samedan logo
 
 
spacer
home > epc > winter 2001 > outsourcing your clinical trial - the search for added value
PUBLICATIONS
European Pharmaceutical Contractor

Outsourcing Your Clinical Trial - The Search for Added Value

From a rational perspective, choosing a clinical research organisation (CRO) should be easy. They are numerous, the competition is high, and the nuts and bolts of all clinical trials are essentially the same. This has created a buyers' market with many clinical research organisations chasing the same work. It would therefore appear that choice of CRO can be determined by two tangible elements, namely price and capacity. To these should be added financial security, evidence of compliance to ICH and some indication that the study staff initiating your project will also be around to see it through to completion.

But is this process really rational? Surely the choice of a CRO should involve a balanced assessment of all potential factors, including those which may be considered 'soft' or difficult to quantify, but which may add significant value to your relationship?

This article will examine the real decisions that have to be made when choosing a contract partner. The examination will involve an honest appraisal of what an organisation should really hope to gain from such a partner in order to add real value to outsourcing activities as opposed to playing safe, basing a decision only on tangibles, and risking a poor return on investment.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Andy Broadhurst, Research Director at Heart Research, UK

Andy Broadhurst studied Biochemistry before joining Wyeth Laboratories as a Pharmacologist, where he completed his PhD in Central Nervous System Pharmacology. Following three years of postdoctoral research at Pierre Fabre Medicament in France, he abandoned the laboratory bench in favour of clinical research at Rhone-Poulenc. He subsequently moved to Syntex Pharmaceuticals and then on to Fujisawa GmbH in Munich as a Clinical Research Manager. Here he focused on the development of tacrolimus in kidney and heart transplantation. In October 1997 Andy joined Heart Research - a CRO specialising in cardiovascular clinical trials - as Research Director.

spacer
Andy Broadhurst
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

3rd Annual Clinical Trial Management Systems (CTMS)

18-19 March 2010, Philadelphia, PA, US

Pharmaceutical and biotech companies are increasingly looking to clinical trial management systems (CTMS) to help streamline their clinical development operations. Building on a successful two-year history, this programme continues to serve as an excellent platform for industry discussion and collaboration among various CTMS stakeholders. This programme addresses the challenges of integrating CTMS systems both within the organisation across various other clinical systems as well as with external systems. Don’t miss this opportunity to hear in-depth industry case studies and learn from the challenges and successes of other companies.  
More info >>

 
News and Press Releases

2010 BIO International Convention Expected to Bring More Than $25 Million to Chicago

The Biotechnology Industry Organization announced today that the 2010 BIO International Convention is expected to contribute more than $25 million to the local economy, according to estimates from the Chicago Convention and Tourism Bureau. The BIO International Convention returns to Chicago on 3rd-6th May and is expected to draw 15,000 to 17,000 industry leaders from 48 states and 60 countries.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement